4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Shanghai INT Medical Instruments Co., Ltd. (1501) operates in the Medical Instruments & Supplies industry and is headquartered in Shanghai, China with about 2,088 employees. Its market capitalization is roughly CNY 7 billion. In the fiscal year ended 2025-12-31, 1501 reported CNY 1.1B in revenue and CNY 219M in net income.
Shanghai INT Medical Instruments Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, and sale of cardiovascular interventional medical devices in Mainland China, Europe, the United States, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 1.1B | CNY 852M | CNY 753M | CNY 586M | — |
| Gross Profit | CNY 637M | CNY 538M | CNY 438M | CNY 332M | — |
| Operating Income (EBIT) | CNY 259M | CNY 215M | CNY 162M | CNY 123M | — |
| Net Income | CNY 219M | CNY 192M | CNY 175M | CNY 144M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | — | (CNY 47M) | (CNY 40M) | (CNY 44M) | (CNY 47M) |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 3.1B | CNY 2.3B | CNY 2.0B | CNY 1.8B | — |
| Total Liabilities | CNY 1.0B | CNY 473M | CNY 351M | CNY 273M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1501 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms